For Immediate Release 17 January 2005

The Medical House PLC

Technology Day to be held on 1 February 2005

Medical House PLC ("TMH"), (AIM:MLH) the orthopaedic devices and drug
delivery company, is pleased to announce that they will be holding a technology day on 1 February 2005, for investors, analysts and press at

Buchanan Communications
107 Cheapside
EC2V 6DN.

For further information

The Medical House PLC
Ian Townsend, Executive Chairman
0114 261 9011
www.themedicalhouse.com

Buchanan Communications
Tim Anderson/Lisa Baderoon/Rebecca Skye Dietrich
0207 7466 5000

Notes to Editors:

About Medical House - Market Background

TMH has progressively been developing needle-free devices which are already successfully used in the market. TMH's own proprietary next generation device, the SQ-Pen, its latest spring powered re-usable system, has great potential in drug delivery worldwide. TMH also has several distribution agreements in place for the insulin market with its first needle-free device, named the mhi-500.

TMH announced in November 2002 that it had received approval from the PPA (Prescription Pricing Authority) for the admission of the mhi-500 device to the NHS Drug Tariff, to be effective from 1 January 2003. This has enabled the device and the related consumables to be prescribed on a free-of-charge basis to the more than 500,000 people with diabetes in the UK who inject insulin daily. This makes the mhi-500 the first needle-free injection system for liquid pharmaceuticals to be available on the UK NHS Drug Tariff. The market for human growth hormone drugs is expected to reach $2.2 billion by 2006 according to AS Insights.

TMH currently has distribution agreements already in place for its needle-free injection systems for insulin use covering: Australia; the Southern Africa Development Communities (including South Africa, Angola, Namibia, Botswana, Zambia, Swaziland, Zimbabwe, Malawi, Mozambique and Lesotho); Israel; Belgium, Holland, Luxembourg, Turkey; Canada; Egypt, New Zealand, China, Poland, Pakistan, Morocco and Ireland.

Historically the majority of the Group's turnover has come from its orthopaedic company, Eurocut Limited. It designs and manufactures instruments and systems used in orthopaedic procedures for many of the world's leading orthopaedic companies. Eurocut was established in 1988 and now has a reputation as one of Europe's leading orthopaedic instrument businesses.

In January 2004, the company moved into significantly enlarged premises enabling it to expand sales significantly. This enables Eurocut to take advantage of a growing orthopaedic market which has an increasing demand for ever more complex instrumentation to carry out minimally invasive and image guided procedures.

- END -